These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32927458)

  • 1. Genotype-Guided Hydralazine Therapy.
    Collins KS; Raviele ALJ; Elchynski AL; Woodcock AM; Zhao Y; Cooper-DeHoff RM; Eadon MT
    Am J Nephrol; 2020; 51(10):764-776. PubMed ID: 32927458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy.
    Han LW; Ryu RJ; Cusumano M; Easterling TR; Phillips BR; Risler LJ; Shen DD; Hebert MF
    J Clin Pharmacol; 2019 Dec; 59(12):1678-1689. PubMed ID: 31257615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension.
    Spinasse LB; Santos AR; Suffys PN; Muxfeldt ES; Salles GF
    Pharmacogenomics; 2014 Feb; 15(2):169-78. PubMed ID: 24444407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure.
    Garcés-Eisele SJ; Cedillo-Carvallo B; Reyes-Núñez V; Estrada-Marín L; Vázquez-Pérez R; Juárez-Calderón M; Guzmán-García MO; Dueñas-González A; Ruiz-Argüelles A
    J Clin Pharm Ther; 2014 Aug; 39(4):368-75. PubMed ID: 24702251
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Allen CE; Doll MA; Hein DW
    Drug Metab Dispos; 2017 Dec; 45(12):1276-1281. PubMed ID: 29018032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
    Gonzalez-Fierro A; Vasquez-Bahena D; Taja-Chayeb L; Vidal S; Trejo-Becerril C; Pérez-Cardenas E; de la Cruz-Hernández E; Chávez-Blanco A; Gutiérrez O; Rodriguez D; Fernandez Z; Duenas-González A
    Int J Clin Pharmacol Ther; 2011 Aug; 49(8):519-24. PubMed ID: 21781652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on N-Acetyltransferase (NAT2) Genotype Relationships in Emiratis: Confirmation of the Existence of Phenotype Variation among Slow Acetylators.
    Al-Ahmad MM; Amir N; Dhanasekaran S; John A; Abdulrazzaq YM; Ali BR; Bastaki S
    Ann Hum Genet; 2017 Sep; 81(5):190-196. PubMed ID: 28653770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.
    Suvichapanich S; Fukunaga K; Zahroh H; Mushiroda T; Mahasirimongkol S; Toyo-Oka L; Chaikledkaew U; Jittikoon J; Yuliwulandari R; Yanai H; Wattanapokayakit S; Tokunaga K
    Pharmacogenet Genomics; 2018 Jul; 28(7):167-176. PubMed ID: 29781872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.
    Hein DW; Millner LM
    Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):9-21. PubMed ID: 33094670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-acetyltransferase 2 acetylator genotype-dependent N-acetylation of 4-aminobiphenyl in cryopreserved human hepatocytes.
    Habil MR; Doll MA; Hein DW
    Pharmacogenet Genomics; 2020 Apr; 30(3):61-65. PubMed ID: 31895247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Rapid Pharmacogenomic Assay to Detect
    Verma R; Patil S; Zhang N; Moreira FMF; Vitorio MT; Santos ADS; Wallace E; Gnanashanmugam D; Persing DH; Savic RM; Croda J; Andrews JR
    Am J Respir Crit Care Med; 2021 Dec; 204(11):1317-1326. PubMed ID: 34375564
    [No Abstract]   [Full Text] [Related]  

  • 12. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
    Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
    Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
    Wattanapokayakit S; Mushiroda T; Yanai H; Wichukchinda N; Chuchottawon C; Nedsuwan S; Rojanawiwat A; Denjanta S; Kantima T; Wongyai J; Suwankesawong W; Rungapiromnan W; Kidkeukarun R; Bamrungram W; Chaiwong A; Suvichapanich S; Mahasirimongkol S; Tokunaga K
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1364-1369. PubMed ID: 27725049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylator phenotype and the antihypertensive response to hydralazine.
    Jounela AJ; Pasanen M; Mattila MJ
    Acta Med Scand; 1975 Apr; 197(4):303-6. PubMed ID: 1136859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cigarette smoking, N-acetyltransferase 2 polymorphisms and systemic lupus erythematosus in a Japanese population.
    Kiyohara C; Washio M; Horiuchi T; Tada Y; Asami T; Ide S; Takahashi H; Kobashi G;
    Lupus; 2009 Jun; 18(7):630-8. PubMed ID: 19433464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-acetyltransferase 2 polymorphism and acetylation profiles in Buginese ethnics of Indonesia.
    Yuliwulandari R; Susilowati RW; Razari I; Viyati K; Umniyati H; Prayuni K
    Ann Hum Genet; 2019 Nov; 83(6):465-471. PubMed ID: 31332782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders.
    Hirvonen A; Saarikoski ST; Linnainmaa K; Koskinen K; Husgafvel-Pursiainen K; Mattson K; Vainio H
    J Natl Cancer Inst; 1996 Dec; 88(24):1853-6. PubMed ID: 8961976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of Syrian hamster lines congenic at the polymorphic acetyltransferase locus (NAT2): acetylator genotype-dependent N- and O-acetylation of arylamine carcinogens.
    Hein DW; Doll MA; Rustan TD; Gray K; Ferguson RJ; Feng Y
    Toxicol Appl Pharmacol; 1994 Jan; 124(1):16-24. PubMed ID: 8291057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis.
    Yee J; Kim SM; Han JM; Lee N; Yoon HY; Gwak HS
    Sci Rep; 2020 Feb; 10(1):3658. PubMed ID: 32107440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.
    Cordes H; Thiel C; Aschmann HE; Baier V; Blank LM; Kuepfer L
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6134-45. PubMed ID: 27480867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.